Back to Top Friday, May 13
Bevacizumab Combined With Chemotherapy Prolongs Survival for Some Patients with Advanced Lung Cancer
(Posted: 03/14/2005, Updated: 05/13/2005) - Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (Avastin™) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.
Saturday, May 14
Sentinel Node Biopsy Helps Some Melanoma Patients Live Longer
(Posted: 05/14/2005, Updated: 10/02/2006) - A technique called lymphatic mapping and sentinel-node biopsy - which looks for cancer in a few lymph nodes first - was better than a "watch and wait" approach in helping melanoma patients whose cancer had spread to the lymph nodes to live longer, according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.

Study Fails to Confirm That Irinotecan is Superior in Extensive-Stage Small Cell Lung Cancer
(Posted: 05/14/2005) - In contrast to earlier findings, irinotecan and cisplatin were no better than the standard treatment at helping patients with extensive small-call lung cancer live longer, according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.

Erlotinib Plus Gemcitabine Boosts One-Year Survival in Pancreatic Cancer
(Posted: 05/14/2005, Reviewed: 10/06/2007) - Patients with advanced pancreatic cancer who were treated with the drug erlotinib (Tarceva®) in addition to gemcitabine had modest improvement in one-year survival rates compared to patients treated with gemcitabine alone, according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.

Adding Bevacizumab (Avastin®) Improves Outcomes in Advanced Colorectal Cancer
(Posted: 05/14/2005, Reviewed: 05/01/2007) - Patients with advanced colorectal cancer lived longer and went longer without disease progression when their FOLFOX chemotherapy regimen was supplemented with bevacizumab (Avastin®), according to findings presented at the American Society of Clinical Oncology.
Sunday, May 15
Lenalidomide Reduces Need for Blood Transfusions in Myelodysplastic Syndrome
(Posted: 05/15/2005) - Lenalidomide (Revlimid™) reduced the need for blood transfusions in some patients with myelodysplastic syndrome (MDS), according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.

Adding Docetaxel Improves Survival in Stomach Cancer
(Posted: 05/15/2005, Updated: 11/13/2006) - Addition of the drug docetaxel (Taxotere®) to other chemotherapy drugs used to treat advanced stomach cancer increased the number of patients surviving for at least two years, according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.

Rituximab Helps Patients with Recurrent Lymphomas
(Posted: 10/26/2005, Updated: 11/01/2006) - Two studies from Germany showed the targeted therapy rituximab (Rituxan®) to be effective in treating recurrent or refractory follicular and mantle cell lymphomas. Findings from these studies were presented at the 2005 and 2006 annual meetings of the American Society of Clinical Oncology.
Monday, May 16
Low-Fat Diet May Reduce Risk of Breast Cancer Relapse
(Posted: 05/16/2005, Reviewed: 01/08/2007) - Postmenopausal women who ate a low-fat diet were less likely to get a recurrence of breast cancer than those who ate a standard diet, according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.
Tuesday, May 17
Methylnaltrexone Relieves Constipation Caused by Pain Medication
(Posted: 06/01/2005) - Seriously ill patients in hospice or palliative care settings who were constipated from their pain medications got significant relief from the drug methylnaltrexone, according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.

Dexmethylphenidate Reduces Some Symptoms of Chemobrain
(Posted: 06/01/2005) - Cancer patients diagnosed with chemotherapy-related fatigue and cognitive impairment ("chemobrain") were helped by the drug dexmethylphenidate (Focalin®), according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.